Human IgG and IgA responses to COVID-19 mRNA vaccines

被引:136
作者
Wisnewski, Adam, V [1 ]
Luna, Julian Campillo [1 ]
Redlich, Carrie A. [1 ]
机构
[1] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA
关键词
HALF-LIVES; ANTIBODY; IMMUNOGLOBULINS; IMMUNITY; KINETICS; SERUM;
D O I
10.1371/journal.pone.0249499
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
SARS-CoV-2 spike antigen-specific IgG and IgA elicited by infection mediate viral neutralization and are likely an important component of natural immunity, however, limited information exists on vaccine induced responses. We measured COVID-19 mRNA vaccine induced IgG and IgA in serum serially, up to 145 days post vaccination in 4 subjects. Spike antigen-specific IgG levels rose exponentially and plateaued 21 days after the initial vaccine dose. After the second vaccine dose IgG levels increased further, reaching a maximum approximately 7-10 days later, and remained elevated (average of 58% peak levels) during the additional >100 day follow up period. COVID-19 mRNA vaccination elicited spike antigen-specific IgA with similar kinetics of induction and time to peak levels, but more rapid decline in serum levels following both the 1(st) and 2(nd) vaccine doses (<18% peak levels within 100 days of the 2(nd) shot). The data demonstrate COVID-19 mRNA vaccines effectively induce spike antigen specific IgG and IgA and highlight marked differences in their persistence in serum.
引用
收藏
页数:7
相关论文
共 28 条
[1]   Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults [J].
Anderson, E. J. ;
Rouphael, N. G. ;
Widge, A. T. ;
Jackson, L. A. ;
Roberts, P. C. ;
Makhene, M. ;
Chappell, J. D. ;
Denison, M. R. ;
Stevens, L. J. ;
Pruijssers, A. J. ;
McDermott, A. B. ;
Flach, B. ;
Lin, B. C. ;
Doria-Rose, N. A. ;
O'Dell, S. ;
Schmidt, S. D. ;
Corbett, K. S. ;
Swanson, P. A., II ;
Padilla, M. ;
Neuzil, K. M. ;
Bennett, H. ;
Leav, B. ;
Makowski, M. ;
Albert, J. ;
Cross, K. ;
Edara, V. V. ;
Floyd, K. ;
Suthar, M. S. ;
Martinez, D. R. ;
Baric, R. ;
Buchanan, W. ;
Luke, C. J. ;
Phadke, V. K. ;
Rostad, C. A. ;
Ledgerwood, J. E. ;
Graham, B. S. ;
Beigel, J. H. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (25) :2427-2438
[2]  
[Anonymous], NAT MED
[3]   COVID-19 Vaccines May Not Prevent Nasal SARS-CoV-2 Infection and Asymptomatic Transmission [J].
Bleier, Benjamin S. ;
Ramanathan, Murugappan, Jr. ;
Lane, Andrew P. .
OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2021, 164 (02) :305-307
[4]   IMMUNOGLOBULINS IN THE LUNG [J].
BURNETT, D .
THORAX, 1986, 41 (05) :337-344
[5]  
CURTIS J, 1973, IMMUNOLOGY, V24, P147
[6]   Antibodies and B cell memory in viral immunity [J].
Doerner, Thomas ;
Radbruch, Andreas .
IMMUNITY, 2007, 27 (03) :384-392
[7]   An mRNA Vaccine against SARS-CoV-2-Preliminary Report [J].
Jackson, L. A. ;
Anderson, E. J. ;
Rouphael, N. G. ;
Roberts, P. C. ;
Makhene, M. ;
Coler, R. N. ;
McCullough, M. P. ;
Chappell, J. D. ;
Denison, M. R. ;
Stevens, L. J. ;
Pruijssers, A. J. ;
McDermott, A. ;
Flach, B. ;
Doria-Rose, N. A. ;
Corbett, K. S. ;
Morabito, K. M. ;
O'Dell, S. ;
Schmidt, S. D. ;
Swanson, P. A. ;
Padilla, M. ;
Mascola, J. R. ;
Neuzil, K. M. ;
Bennett, H. ;
Sun, W. ;
Peters, E. ;
Makowski, M. ;
Albert, J. ;
Cross, K. ;
Buchanan, W. ;
Pikaart-Tautges, R. ;
Ledgerwood, J. E. ;
Graham, B. S. ;
Beigel, J. H. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (20) :1920-1931
[8]   A SARS-CoV-2 mRNA Vaccine - Preliminary Report [J].
Jackson, Lisa A. ;
Roberts, Paul C. ;
Graham, Barney S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (12) :1190-1192
[9]  
Klingler Jeromine, 2020, medRxiv, DOI 10.1101/2020.08.18.20177303
[10]   CROSS-PROTECTION IN MICE INFECTED WITH INFLUENZA-A VIRUS BY THE RESPIRATORY ROUTE IS CORRELATED WITH LOCAL IGA ANTIBODY RATHER THAN SERUM ANTIBODY OR CYTO-TOXIC T-CELL REACTIVITY [J].
LIEW, FY ;
RUSSELL, SM ;
APPLEYARD, G ;
BRAND, CM ;
BEALE, J .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1984, 14 (04) :350-356